ChemotherapyFDA-approvedFirst-line
Alimta
Generic name: pemetrexed
How it works
Interferes with the growth and spread of cancer cells by blocking the production of DNA and RNA.
Cancer types
Lung Cancer— All patients
Efficacy
Studies show that patients treated with Alimta have a median overall survival of approximately 10 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a New Approach to Treat Lung Cancer Spreading to the Brain and Spinal Cord | Lung Cancer | preclinical | — | Source → |
| Pemetrexed Enhances γδ T Cell Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Testing a New Treatment Combination for Unresectable Pleural Mesothelioma | Lung Cancer | phase-3 | — | Source → |
| Rare Skin Reaction Linked to Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| New Treatment Combination Tested for Lung Cancer Patients with Brain Metastases | Lung Cancer | phase-1 | — | Source → |
| Testing Methoxyamine with Cisplatin and Pemetrexed in Advanced Cancer Patients | Lung Cancer | phase-1 | — | Source → |
| Testing Sacituzumab Tirumotecan in Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Traditional Chinese Medicine May Help Reduce Chemotherapy Side Effects in Lung Cancer Patients | Lung Cancer | phase-3 | The incidence of neurotoxicity was 29.1% in the treatment group, significantly lower than 51.8% in the control group. | Source → |
| Combining Medications Improves Lung Cancer Treatment for Some Patients | Lung Cancer | phase-3 | Combination therapy significantly prolonged median progression-free survival compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34-0.97). | Source → |
| Taxane Chemotherapy May Be More Effective Than Pemetrexed in Lung Cancer | Lung Cancer | observational | Taxanes showed numerically longer progression-free survival (PFS; median 8.8 vs 7.9 months) and overall survival (OS; 18.8 vs 15.9 months) versus pemetrexed. | Source → |
| Pemetrexed Side Effects Study Identifies New Safety Signals | Lung Cancer | observational | — | Source → |
| New Treatment Combination Shows Promise for Lung Cancer Patient | Lung Cancer | observational | The treatment successfully prolonged the patient's survival by 3 months. | Source → |
| New Biomarkers for Lung Cancer Treatment Identified | Lung Cancer | lab-study | The Random forest model had an area under the curve (AUC) of 0.981 for diagnosing patients with NSCLC and 0.954 for evaluating pemetrexed efficiency. | Source → |
| Rare Lung Cancer Case Shows Long-Term Survival with Pemetrexed Treatment | Lung Cancer | observational | She has been taking entrectinib for over 20 months. | Source → |
| Combining Osimertinib and Pemetrexed May Help Treat Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Alternate Dosing Schedule for Lung Cancer Treatment May Improve Survival | Lung Cancer | observational | OS trended towards better survival among patients receiving the alternate schedule regimen (11.9 vs 18.1 months, p =0.3). | Source → |
| Pemetrexed May Help Treat Non-Small-Cell Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Pemetrexed's Effect on Lung Cancer Cells Varies with Glucose Levels | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.